Stockreport

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF - Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months -- At These Doses, P [Read more]